EcoR1 Capital’s Denali Therapeutics DNLI Stock Holding History

EcoR1 Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-733,561	Closed	-$17.7M	–	53
2020 Q2	$17.7M	Buy	733,561 +35,460	+5%	+$834K	1.31%	21
2020 Q1	$12.2M	Buy	+698,101	New	+$14.6M	1.28%	23
2018 Q2	–	Sell	-325,000	Closed	-$6.4M	–	37
2018 Q1	$6.4M	Buy	325,000 +125,000	+63%	+$2.57M	0.64%	26
2017 Q4	$3.13M	Buy	+200,000	New	+$3.59M	0.35%	27

Other funds holding DNLI

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital's DNLI Position: Q3 2020 in Review

EcoR1 Capital sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 733,561 shares — an estimated $17.7M sold.

EcoR1 Capital first reported a position in DNLI in Q4 2017 and held it in 4 quarters. The position peaked at $17.7M in Q2 2020. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

EcoR1 Capital reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
EcoR1 Capital sold 733,561 Denali Therapeutics shares in Q3 2020, an estimated $17.7M.
EcoR1 Capital first reported a position in Denali Therapeutics in Q4 2017 and held it in 4 quarters.
EcoR1 Capital's Denali Therapeutics position peaked at $17.7M in Q2 2020.
170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on EcoR1 Capital's 13F filing for Q3 2020, filed 16 Nov 2020.